The Accelerated Approval Backlash: Was Oxbryta Rushed to Market? 

Explore why Oxbryta faced backlash after accelerated approval. Learn what new safety data revealed and how it affected the drug's status in the US.
Accelerated approval for Oxbryta.

Table of Contents

Don't miss out on monthly updates

Subscribe to our newsletter and stay ahead of the verdicts.

For families living with sickle cell disease, a diagnosis does not just bring pain. It brings the exhausting reality of watching treatment options run out one by one. So when the FDA approved Oxbryta in 2019, the response was not just relief. It was the kind of hope that people hold onto when they have been waiting a very long time. 

Within five years, that drug was pulled from the global market entirely. 

Post-marketing data showed that patients on Oxbryta were experiencing higher rates of the very crises the drug was supposed to prevent, along with organ damage and deaths that had not appeared in early trials.  

The lawsuits that followed raised a harder question than simply whether the drug worked: did the system that approved it do its job? If the FDA’s accelerated pathway is meant to protect the most vulnerable patients, how did this happen to them first? 

What the Oxbryta Case Actually Reveals 

  • FDA accelerated approval is designed to speed up access for patients with serious conditions, but it does not mean a drug has been proven safe or fully effective. 
  • Oxbryta was prescribed to thousands of sickle cell patients based on a surrogate endpoint, a laboratory marker, rather than evidence of real clinical benefit. 
  • The same system meant to protect vulnerable patients allowed a drug with serious safety signals to remain on the market long after those signals emerged. 
  • Withdrawal does not end the consequences. Patients who were harmed during the drug’s time on the market are left with lasting damage and unanswered questions. 
“
The devil takes a hand in what is done in haste. -Turkish Proverb
”

Oxbryta and the Hope It Carried for Sickle Cell Patients 

The drug, Oxbryta, was developed by Global Blood Therapeutics and later acquired by Pfizer. It was granted accelerated approval by the FDA in November 2019 for the treatment of Sickle Cell Disease (SCD) in patients aged 12 years and older. The approval was later extended in 2021 to include children below the age of 12 as well. 

Sickle cell disease is an inherited blood disorder that affects about 100,000 people in the United States, primarily impacting those of Black or African American descent. It is a genetic disease caused by a mutation that changes the shape of red blood cells into a sickle shape.  

The sickle shape causes early destruction of red blood cells, interrupted blood flow, causing sickle cell crises or vaso-occlusive crises (VOC), chronic pain, damage to organs, and decreased life expectancy. 

Oxbryta didn’t just treat the symptoms; it aimed to address the underlying cause of inhibiting sickle hemoglobin polymerization, addressing the root cause of SCD.  The accelerated approval was based on early clinical trials showing improvements in hemoglobin levels and a reduction in anemia-related complications.  

Image showing Oxbryta information, including its generic name, functions, and treatment purpose.

How Accelerated Approval Works? 

The FDA’s accelerated approval pathway was created to move promising treatments to patients faster when the disease is serious, existing options are limited, and waiting for long-term outcome data would cost lives. The tradeoff built into the system is this: approval can be granted based on a surrogate endpoint, a measurable biological marker that is expected to predict clinical benefit, rather than waiting for direct evidence. 

For Oxbryta, that surrogate endpoint was an increase in hemoglobin levels. Higher hemoglobin suggested healthier red blood cells, which was a reasonable basis for optimism. The pathway does not end at approval, though. Drug manufacturers have to run confirmatory trials after a drug reaches the market to validate that the surrogate benefit actually translates into the real-world outcomes patients care about. 

The goal the pathway is designed to achieve includes: 

  • Getting therapies to patients with serious conditions faster than the standard approval timeline allows 
  • Providing early access when the need is urgent and alternatives are genuinely scarce 
  • Maintaining a post-approval accountability structure through required confirmatory trials 

The mechanism is not reckless by design. The problem is what happens when that post-approval accountability structure does not catch problems quickly enough. 

When the Safety Data Told a Different Story 

Despite the early optimism, post-marketing data painted a picture that conflicted sharply with the clinical trial results that had supported Oxbryta’s approval. 

According to data by the Medicaid Evidence Review and Cost Initiative (MERCI), patients taking Oxbryta experienced higher rates of vaso-occlusive crises and more deaths compared to those receiving a placebo. The very crisis events that Oxbryta was designed to reduce were occurring at elevated rates in patients taking the drug. 

Additional safety concerns reported during the post-marketing period included: 

  • Severe allergic reactions, including rashes and swelling of the lips and tongue 
  • Signs of blood clots, including chest pain and shortness of breath 
  • Gastrointestinal problems such as stomach pain and diarrhea 
  • Headache and nausea 

In September 2024, both the FDA and the European Medicines Agency recommended a global recall of Oxbryta. The manufacturer withdrew the drug voluntarily.  

A drug approved on the basis of a surrogate marker had failed to demonstrate real clinical benefit and had been associated with serious harm in the patient population. 

The Lawsuits That Followed 

The withdrawal of Oxbryta did not close the chapter for the families affected by it. It opened a legal one. 

Lawsuits began mounting against Pfizer and Global Blood Therapeutics, with plaintiffs alleging that the rush to bring Oxbryta to market had come at the direct expense of patient safety. Filings in New Jersey alone described patients suffering multiple vaso-occlusive crises and extended hospitalizations. Earlier cases reported organ damage, strokes, and wrongful deaths attributed to the drug. 

Across these cases, the core allegations follow a consistent pattern. Plaintiffs argued that the manufacturers: 

  • Failed to adequately warn patients and healthcare providers about the drug’s known and potential side effects 
  • Did not conduct sufficient safety testing before and after approval 
  • Prioritized financial returns over the well-being of a vulnerable patient population 

The lawsuits point to several possible commercial pressures behind Oxbryta’s development and launch: 

  • No approved sickle cell disease treatments were available at the time. 
  • Speed to market may have been seen as critical. 
  • Competitor pressure may have influenced launch timing. 
  • High demand and no alternatives created major revenue potential. 
  • Rare disease drugs can offer strong long-term commercial value. 

These factors are not unique to Oxbryta, which is why the case may have broader implications for the pharmaceutical industry. 

The Question the FDA Needs to Answer 

Oxbryta is off the market. The lawsuits are moving through the courts, and the system appears to be working exactly as it was designed to. 

Which is precisely what makes this concerning. 

The accelerated approval pathway did not malfunction here. A drug reached patients faster than standard timelines would have allowed, post-marketing data eventually surfaced the risks, and the drug was withdrawn. Every step followed the playbook. The problem is that somewhere between approval and withdrawal, real patients got sicker. 

The FDA has not announced any fundamental changes to how accelerated approvals are monitored. Pharmaceutical companies are still running the same post-marketing trial timelines, and thousands of patients with serious, underserved conditions are still being prescribed drugs approved on surrogate endpoints. 

Oxbryta may have been withdrawn–but the conditions that put it in patients’ hands in the first place are still very much in place. 

FAQs 

guest

0 Comments
Oldest
Newest Most Voted
You might also like
Receive the latest news

Subscribe To Our Newsletter

Get notified about new articles

0
Would love your thoughts, please comment.x
()
x